The latest on Peptide Receptor Radionuclide Therapy (PRRT) as of March 23, 2016

~ Tricia Wahmann-Knatz

Happy Saturday, Zebra family! I hope everyone is having a great weekend!

As many may already know, because this is a week and a half later than I would’ve liked (Yay for being a new blog and having so much content to get up this week!), on March 23rd, 2016, there was some breaking news concerning PRRT here in the USA:

“AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare professionals and patients can learn more about the Lutathera EAP by visiting www.clinicaltrials.gov (trial number: NCT02705313).” (Direct link here)

To read or download the whole article, click here.

For more information on Advanced Accelerator Applications (AAA), click here.

For those of you who would like to learn about PRRT, please read my intro to PRRT post for more information!

Best,

Tricia Wahmann-Knatz

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s